glp 1 history of pancreatitis PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic and effect their activation by a GLP-1R agonist Evolution of incretin therapeutics. (A)

After multiple adjustment, sex (OR 2.25, CI95% 1.20-4.19, p = 0.011), NLR (OR 1.01, CI95% 1.03-1.16, p = 0.002) and Slow activity (OR 2.84, CI95% 1.31-6.23, p = 0.008) remain significantly associated with ED

Vandal et al., 2017) is a much easier task than downscaling modeled low-resolution data (e.g., short-term forecasts as in Harris et al

Tirzepatide (Mounjaro, Zepbound) , a dual GIP/GLP-1 receptor agonist, has shown even greater results

As with any medication, its vital to have a comprehensive understanding and professional guidance to reap the benefits effectively and safely

Daza-Arnedo et al., 2023), may reduce bias when evaluating their metabolic effects